ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > Protein > IL-10 R alpha > ILR-H82F6

Biotinylated Human IL-10 R alpha / CD210 Protein, Fc,Avitag™ (MALS verified)

  • Synonym
    Interleukin-10 receptor subunit alpha,IL-10 receptor subunit alpha,IL-10R subunit alpha,IL-10RA,CDw210a,Interleukin-10 receptor subunit 1,IL-10R subunit 1,IL-10R1,CD210,IL10RA,IL10R
  • Source
    Biotinylated Human IL-10 R alpha, Fc,Avitag(ILR-H82F6) is expressed from human 293 cells (HEK293). It contains AA His 22 - Asn 235 (Accession # Q13651-1).
    Predicted N-terminus: His 22
  • Molecular Characterization
    IL-10 R alpha Structure

    This protein carries a human IgG1 Fc tag at the C-terminus, followed by an Avi tag (Avitag™).

    The protein has a calculated MW of 52.5 kDa. The protein migrates as 65-80 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Labeling
    Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
  • Protein Ratio
    Passed as determined by the HABA assay / binding ELISA.
  • Endotoxin
    Less than 1.0 EU per μg by the LAL method.
  • Purity

    >95% as determined by SDS-PAGE.

    >90% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, 25 mM Arginine, 150 mM NaCl, pH7.5 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
SDS-PAGE
IL-10 R alpha SDS-PAGE

Biotinylated Human IL-10 R alpha, Fc,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

SEC-MALS
IL-10 R alpha MALS images

The purity of Biotinylated Human IL-10 R alpha, Fc,Avitag (Cat. No. ILR-H82F6) is more than 90% and the molecular weight of this protein is around 124-152 kDa verified by SEC-MALS.

Bioactivity-ELISA
 IL-10 R alpha ELISA

Immobilized Human IL-10, His Tag (Cat. No. IL0-H4248) at 5 μg/mL (100 μL/well) can bind Biotinylated Human IL-10 R alpha, Fc,Avitag (Cat. No. ILR-H82F6) with a linear range of 0.2-10 ng/mL (QC tested).

Bioactivity-BLI
 IL-10 R alpha BLI

Loaded Biotinylated Human IL-10 R alpha, Fc,Avitag (Cat. No. ILR-H82F6) on SA Biosensor, can bind Human IL-10, His Tag (Cat. No. IL0-H4248) with an affinity constant of 0.72 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

  • Background
    Interleukin-10 receptor subunit alpha (IL-10 R alpha ) is a cell surface receptor for the cytokine IL-10 that participates in IL-10 mediated anti-inflammatory functions, limiting excessive tissue disruption caused by inflammation. Upon binding to IL10, induces a conformational change in IL10RB, allowing IL10RB to bind IL10 as well.In turn, the heterotetrameric assembly complex, composed of two subunits of IL10RA and IL10RB, activates the kinases JAK1 and TYK2 that are constitutively associated with IL10RA and IL10RB respectively.These kinases then phosphorylate specific tyrosine residues in the intracellular domain in IL10RA leading to the recruitment and subsequent phosphorylation of STAT3.
  • Clinical and Translational Updates

コメント (0)


ETD of in-stock products: 4 business days

価格(JPY) : 98,000

価格(JPY) : 425,600

人気商品のおすすめ
ストレプトアビジンコートプレート

価格(JPY) : 8,960

価格(JPY) : 38,360

ストレプトアビジン-HRP

価格(JPY) : 14,000

価格(JPY) : 33,600

Magnetic Beads™ 磁気ビーズ

価格(JPY) : 38,640

価格(JPY) : 64,400

プロモーション&展示



医薬品開発状況

  • Number of Launched Drugs:0 Details
  • Number of Drugs in Clinical Trials:8 Details
  • Latest Research Phase:Phase 3 Clinical

データシート&ドキュメンテーション

DMF請求
DMF (Drug Master File)

関連製品一覧

新製品

お問い合わせ&コメント

This web search service is supported by Google Inc.

totopphone